- Home
- DELL vs GILD Comparison
DELL vs GILD Comparison
Compare DELL & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DELL | GILD |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.7B | 168.6B |
| IPO Year | 2013 | 2003 |
Fundamental Metrics
Financial Performance| Metric | DELL | GILD |
|---|---|---|
| Price | $404.27 | $127.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 18 |
| Target Price | ★ $181.63 | $148.39 |
| AVG Volume (30 Days) | ★ 9.8M | 6.7M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | 1.23% | ★ 2.55% |
| EPS Growth | 36.05 | ★ 1684.21 |
| EPS | ★ 5.24 | 1.61 |
| Revenue | ★ $113,538,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $26.19 | $4.68 |
| Revenue Next Year | $8.60 | $6.04 |
| P/E Ratio | $78.04 | ★ $77.05 |
| Revenue Growth | ★ 18.80 | 9.98 |
| 52 Week Low | $110.22 | $107.19 |
| 52 Week High | $469.47 | $157.29 |
Technical Indicators
Market Signals| Indicator | DELL | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 66.36 | 43.65 |
| Support Level | $126.13 | $116.55 |
| Resistance Level | $469.47 | $126.46 |
| Average True Range (ATR) | 28.95 | 3.62 |
| MACD | -3.29 | -0.34 |
| Stochastic Oscillator | 60.94 | 31.82 |
Price Performance
Historical ComparisonAbout DELL Dell Technologies Inc.
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners and also relies heavily on channel partners to fulfill its sales.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).